REFERENCES
- Maggiolo F. Efavirenz: a decade of clinical experi-ence in the treatment of HIV. J Antimicrob Chemother. 2009;64(5):910–928.
- Pierone G Jr, Mieras J, Martin A, Urban T. Seven-year follow-up on lopinavir/ ritonavir monotherapy. J Int Assoc Physicians AIDS Care. 2009;8(3):191–192.
- Willig J, Abroms S, Westfall A, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008;22:1951–1960.
- Bartlett JA, Fath MJ, Demasi R, et al. An updated system-atic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20(16):2051–2064.
- Riddler SA, Haubrich R, DiRienzo AG, et al. AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–2106.
- Franssen R, Sankatsing RR, Hassink E, et al. Nevirapine increases high-density lipoprotein cholesterol concentra-tion by stimulation of apolipoprotein A-I production. Arte-rioscler Thromb Vasc Biol. 2009;29(9):1336–1341.
- van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiret-roviral-therapy-näive patients infected with HIV-1. PLoS Med. 2004;1(3):e73.
- Parienti JJ, Massari V, Rey D, et al. Efavirenz to nevirap-ine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. Clin Infect Dis. 2007;45(2):263–266.
- Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2006;22(4):321–329
- Colafigli M, Di Giambenedetto S, Bracciale L, et al. Long-term follow-up of nevirapine-treated patients in a single-centre cohort. HIV Med. 2009;10(8):461–469.
- Rodriguez-Arrondo F, Aguirrebengoa K, Portu J, et al. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirap-ine. Curr HIV Res. 2009 Sep;7(5):526–532.
- Mocroft A, Staszewski S, Weber R, et al. EuroSIDA study group. Risk discontinuation of nevirapine due to tox-icities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+T cell counts. Antivir Ther 2007;12:325–333.
- Kesselring A, Wit F, Sabin C et al. Risk factors for treat-ment-limiting toxicities in patients starting nevirapine con-taining antiretroviral therapy. AIDS 2009;23:1689–1699.
- Cooper Cl and Van Heeswijk RPG. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med. 2007;8:1–7.
- Van Leth F, Phanuphak P, Ruxrungtham K et al. Compari-son of first-line antiretroviral therapy with regimens includ-ing nevirapine, efavirenz or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet. 2004;363:1253–1263.
- Soriano V, Köppe S, Mingrone H, et al. Prospective com-parison of nevirapine and atazanavir/ritonavir both com-bined with tenofovir DF/emtricitabine in treatment-naïve HIV-1 infected patients: ARTEN study week 48 results. In: Program and abstracts from the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19–22, 2009; Cape Town, South Africa. Abstract LBPE07.
- Podzamczer D, Olmo M, Sanz J, et al. Safety of switching nevirapine twice daily to nevirapine once daily in virologi-cally suppressed patients. J Acquir Immune Defic Syndr 2009 ;50(4):390–396.
- Hsue PY, Hunt PW, Schnell A, et al. Role of viral replica-tion, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23(9):1059–1067.
- Rodriguez-Arrondo F, Aguirrebengoa K, Portu J, et al. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirap-ine. Curr HIV Res. 2009;7(5):526–532.
- Mastan S, Kumar KE. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetol Metab Syndr 2009;1(1):15.
- Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65–70.
- Kashuba A. Genital compartmentalization of orally and topically administered antiretrovirals. In: Program and abstracts from the 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, Massachusetts. Abstract 95.
- Bonora S, Nicastri E, Calcagno A, et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol. 2009;81(3):400–405.